First in a new class

Sotyktu (plaque psoriasis) is the first in a new class of oral medications to treat plaque psoriasis. An estimated 8 million adults in the U.S. have psoriasis. Last month, the FDA approved Sotyktu (deucravacitinib), the first in a new class of oral medication to treat plaque psoriasis. Will this new product be revolutionary or evolutionary when it comes to plaque psoriasis therapy? ClearScript’s team expects Sotyktu will compete directly with another oral plaque psoriasis therapy (Otezla) for favorable formulary status. This added competition will help contain the cost trend for oral therapies used to treat plaque psoriasis.  

With this information and other pipeline news, ClearScript consults with our clients on how new drugs to market may affect their plans. Also, our partnership with Fairview Specialty Pharmacy provides our clients access to additional data and experience regarding specialty medications. Follow us on LinkedIn to stay up to date on the pipeline or contact us for more information